Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (397)	8/15/2002 6:22:58 PM
From: SemiBull	Respond to of 415

Timothy Noyes Named Chief Operating Officer at Essential Therapeutics, Inc. WALTHAM, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Essential Therapeutics, Inc. (Nasdaq: ETRX - News) today announced the appointment of Timothy Noyes to the position of Chief Operating Officer. Tim joins Essential Therapeutics from Genzyme Corporation where most recently he was President of Genzyme's renal business and its research and development subsidiary, GelTex Pharmaceuticals, Inc. Essential Therapeutics currently has emerging clinical and preclinical programs concentrated in hematology/oncology and infectious disease therapeutic areas. Tim will report directly to Mark Skaletsky, President, Chairman of the Board and Chief Executive Officer at Essential Therapeutics. Mark commented, "We are very proud of Essential Therapeutics' accomplishments in 2002, and believe that Tim will contribute greatly to our continued momentum. His background in pharmaceutical product management and his operational expertise will be critical as the Company further progresses its therapeutic pipeline." "I am excited about the tremendous opportunities at Essential Therapeutics," stated Tim. "I look forward to helping build a successful drug development company." At Genzyme, Tim managed a 250-person renal division responsible for nearly $200 million in annual sales as well as the research and development activities of GelTex. He was involved in the introduction of GelTex's two marketed products, Renagel® and Welchol(TM). Prior to joining GelTex, Tim served in a number of senior positions at Merck & Co., Inc., including Director of Marketing in the Company's hypertension and heart failure division. At Merck, he managed marketing strategy for the cardiovascular agents, Vasotec® and Prinivil®. Combined sales for these two products amounted to over a $1 billion in sales during his tenure. Tim received his M.B.A. from the Harvard Graduate School of Business Administration, and a Bachelor's degree from Harvard College. About Essential Therapeutics Essential Therapeutics, Inc. is committed to the development of breakthrough biopharmaceutical products for the treatment of life-threatening diseases. With an emerging pipeline of lead programs and product candidates in the anti-infective and hematology/oncology therapy areas, Essential Therapeutics is dedicated to commercializing novel small molecule products addressing important unmet therapeutic needs. Additional information on Essential Therapeutics can be obtained at essentialtherapeutics.com. Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Essential Therapeutics. These include, but are not limited to, Essential Therapeutics' ability to: (i) progress its therapeutic pipeline; (ii) develop breakthrough biopharmaceutical products; and (iii) successfully commercialize products. For a discussion of other risks and uncertainties affecting Essential Therapeutics' business, see Essential's Quarterly Report on Form 10-Q for the quarter ended June 30, 2002. Actual results and timing of certain events could differ materially from those indicated in the forward-looking statements as a result of these or other factors. SOURCE: Essential Therapeutics, Inc.